ANNAPOLIS - Annapolis biodefense firm PharmAthene reported $6.8 million in revenue during the third quarter, down from $10.7 million during the same period last year.
The company said its net loss during the third quarter was $14 million, or 50 cents per share, compared to $4.3 million or 20 cents per share during the same period of 2008.
PharmAthene estimates that at its existing sources of cash and cash receipts from contract receivables will be sufficient to fund operations through the end of next year.
"We made excellent progress strengthening our balance sheet and...
| This story has expired! You can purchase the full text in our news archives. |
If you encounter other problems, please email nlundskow@capitalgazette.com and include your name, username, and any errors or messages that are displayed. The more information you can provide, the better able we will be to assist you.
In order to post or vote on a comment, you must be signed in with a hometownannapolis account.
Take a look at a summary of Commenting Guidelines.
If you encounter other problems, please email nlundskow@capitalgazette.com and include your name, username, and any errors or messages that are displayed. The more information you can provide, the better able we will be to assist you.